- Home
- BTBD vs ICU Comparison
BTBD vs ICU Comparison
Compare BTBD & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTBD | ICU |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | 188 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BTBD | ICU |
|---|---|---|
| Price | $1.59 | $3.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 277.7K | 171.3K |
| Earning Date | 03-30-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $93.92 |
| Revenue Next Year | N/A | $39.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $0.22 |
| 52 Week High | $5.59 | $3.77 |
Technical Indicators
Market Signals| Indicator | BTBD | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 67.32 |
| Support Level | $1.20 | $2.26 |
| Resistance Level | $1.59 | N/A |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 25.26 | 69.22 |
Price Performance
Historical ComparisonAbout BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.